FINWIRES · TerminalLIVE
FINWIRES

Neurocrine Biosciences Should See More Upside on Crenessity Growth, RBC Says

By

Neurocrine Biosciences (NBIX) could see more upside from wider Crenessity use, easing insurance limits, stronger patient demand and likely commercial product beats in 2026, RBC Capital Markets said in a note Friday.

RBC said its survey of 35 endocrinologists showed Crenessity still has room to grow after a strong Q1, even as some investors worry near-term demand may slow as surveyed doctors now use Crenessity in about 23% of their Congenital Adrenal Hyperplasia patients on average and expect usage to reach 37% by the end of 2026.

The firm raised its 2026 Crenessity sales estimate to $750 million from $734 million, above the roughly $650 million consensus estimate, saying the target looks achievable even with more cautious growth assumptions and longer-term demand also looks strong, with doctors expecting to use Crenessity in just over half of their CAH patients within five years.

Insurance approvals remain the main barrier to wider use, but RBC expects those issues to ease over time and support further adoption, according to the note.

RBC kept the company's outperform rating and raised its price target to $183 from $180.

Price: $157.29, Change: $+0.90, Percent Change: +0.58%

Related Articles

Wire

Okta Continues to Build Momentum After Strong Q1, RBC Says

Okta (OKTA) reported a strong fiscal Q1 with outperformanceacross the board and a guidance raise, RBC Capital Markets said in a Friday note."Momentum is building for both new products and a GTM perspective with specialization and capacity increase benefits both yielding results," the report said.Based on accelerating current remaining performance obligation growth, additional upside to fiscal 2027 estimates seems likely given strong execution and positive demand signals, it said.The note also said early traction with agentic security remains encouraging and could represent a source of upside.RBC maintained its outperform rating and raised its price target to $122 from $108 on higher estimates.Price: $120.31, Change: $+25.59, Percent Change: +27.02%

$OKTA
Wire

Essential Utilities' Merger With American Water Works Offers Attractive Upside, UBS Says

Essential Utilities' (WTRG) merger with American Water Works (AWK) offers an attractive upside with a 20% total return potential, UBS said in a Friday research report.The company's standalone positives includes a steady credit profile, a low-risk and capital-intensive growth plan, and stable regulatory relations, according to the note.UBS upgraded the stock to buy from neutral and raised its price target to $43 from $41.Price: $36.91, Change: $+0.22, Percent Change: +0.60%

$AWK$WTRG
Wire

Top Midday Gainers

NetApp (NTAP) reported fiscal Q4 non-GAAP earnings and revenue late Thursday above market expectations, and its forecast for the full financial year also beat consensus.Shares soared 27% amid a surge in intraday trading volume to over 6.5 million from a daily average of roughly 2.5 million.Dell Technologies (DELL) reported overnight fiscal Q1 financial results that topped analyst estimates and issued higher-than-expected guidance for fiscal Q2 and the full year.Shares surged 29% as intraday trading volume catapulted to over 27.1 million from a daily average of about 7.99 million.Replimune (REPL) said Friday it will, in the coming days, resubmit a biologics license application with the US Food and Drug Administration for vusolimogene oderparepvec, its experimental treatment for advanced melanoma.Shares catapulted 83% following an increase in intraday trading volume to over 39.8 million from a daily average of about 6.19 million.Price: $180.63, Change: $+38.23, Percent Change: +26.85%

$DELL$NTAP$REPL